Rudy Kessinger

Zach Cummins

Nehal Chokshi

Bradley Clark

- **TAE Life Sciences (TLS)** announced preclinical results demonstrating that its novel boronated drugs, when combined with immune checkpoint inhibitors, **significantly inhibited tumor growth** in preclinical in vivo models, outperforming either immunotherapy alone or Boron Neutron Capture Therapy (BNCT) alone.  **[320121_bbc63685e4f24906bf23273aebbf340f_0]** 
- These findings are consistent with recent independent 2024 studies, reinforcing the potential for **synergistic immune activation** and supporting TLS's BNCT-immunotherapy strategy.  **[320121_bbc63685e4f24906bf23273aebbf340f_0]** 
- Rob Hill, CEO of TLS, stated that these results expand the company's clinical opportunity and strengthen its position in both **oncology and the fast-growing immunotherapy markets**.  **[320121_bbc63685e4f24906bf23273aebbf340f_0]** 
- The research partnership with Kyoto University has been **extended through December 2026** to ensure continuity in preclinical testing and advance the program towards IND-enabling studies.  **[320121_bbc63685e4f24906bf23273aebbf340f_0]**

TELOS (TLS)